









Markets
/
Stocks
/
nasdaq-clrb
/

Cellectar Biosciences Inc

CLRB

View Detailed Chart

4.720USD

-0.120-2.48%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

7.25MMarket Cap

LossP/E TTM



Cellectar Biosciences Inc

4.720

-0.120-2.48%

Overview Company Financials

Financials

Intraday

30m

Today

-2.48%

5 Days

-7.27%

1 Month

-1.67%

6 Months

+1701.53%

Year to Date

+1478.60%

1 Year

+138.38%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

120.000

Target Price

2442.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Cellectar Biosciences Inc

CLRB

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(2)

Buy(3)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.371

Neutral

RSI(14)

51.292

Neutral

STOCH(KDJ)(9,3,3)

17.486

Oversold

ATR(14)

0.405

High Vlolatility

CCI(14)

-132.605

Sell

Williams %R

80.176

Oversold

TRIX(12,20)

0.815

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.816

Sell

MA10

5.054

Sell

MA20

4.973

Sell

MA50

3.395

Buy

MA100

1.845

Buy

MA200

1.384

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

Ticker SymbolCLRB

CompanyCellectar Biosciences Inc

CEOMr. James V. Caruso

Websitehttps://www.cellectar.com/